Microdilution Testing Methodology for Tigecycline: Addition of A Biocatalytic Oxygen-Reducing Agent May Be Required in The **Absence of Fresh Media**

#P 801

T. Stevens¹, B. Johnson¹, S. Bouchillon¹, D. Hoban¹, J. Johnson¹, M. Dowzicky² and P. Bradford²

¹International Health Management Associates, Schaumburg, IL, USA ²Wyeth Pharmaceuticals, Collegeville/Pearl River, PA/NY, USA

ABSTRACT

Background: Tigecycline (TGC) is a new glycylcycline antimicrobial in development. TGC has been evaluated in vitro and quality control ranges were presented to NCCLS. Tentative quality control ranges were determined in fresh broth (<12 hours old). This study looks at the addition of a biocatalytic oxygen-reducing agent (BORA) to aged broth (>12 hours old) as an alternative when performing microdilution testing. **Methods**: Testing was done on approximately 3,400 Enterobacteriaceae, enterococci; H. influenzae (HFL); M. catarrhalis; S. aureus (SA); S. pneumoniae (SP); S. pyogenes and other streptococci. Microdilution panels and broth were prepared by Microscan. Organisms were prepared in water or saline to achieve a 0.5 McFarland standard prior to adding to a broth inoculum. Two identical sets of aged broth tubes, containing appropriate organism media, were used in the study. To one set of broth was added 2% Oxyrase[®] (OXY) for Broth. Each corresponding tube was inoculated with the identical test organism. Quality controls were performed using the following ATCC strains: E. coli 25922, P. aeruginosa 27853, E. faecalis 29212, S. aureus 29213, S. pneumoniae 49619, and H. influenzae 49247. Results: Combined test results showed a 67.02% higher MIC value (1-4 log, dilutions) in the non-OXY panels versus the OXY panels. The impact on MIC_{on} values is significant for some organisms such as: A. baumannii; SA; SP; HFL; C. freundii; and E. faecalis where non-OXY panels produced results higher than OXY panels -2/1, 0.5/0.25, 0.12/0.06, 2/0.12; 1/0.5; and 0.25/0.12, respectively. Quality controls were out of range 29.3% of the time in non-OXY panels and in compliance 100% of the time with OXY panels. Conclusion: The addition of a BORA in aged broth is a viable alternative to performing TGC microdilution testing in fresh broth.

INTRODUCTION

Tigecycline is a novel antimicrobial with an expanded broadspectrum of activity from a new class of compounds, glycylcyclines. Tigecycline inhibits protein synthesis by binding to the 30S ribosomal subunit. Although it is perceived to be bacteriostatic, its anti-bacterial activity is significant and has shown some bactericidal activity against key targeted pathogens [1,2].. Currently, tigecycline is being developed for use in a broad range of infections and against both Gram-positive and -negative bacteria.

Recently, it was noted that freshly prepared or frozen panels using aged broth (>12 hours old) may produce MICs higher than those seen with panels using fresh broth (<12 hours old). This has led to a recommendation that tigecvcline be tested using fresh broth to ensure MICs are correctly reported. Work has been performed by Wyeth Pharmaceuticals on the addition of a biocatalytic oxygen-reducing agent (BORA) to aged broth in an effort to compensate for the tigecvcline MIC discrepancies between aged and fresh broth.

Extensive in vitro testing is now underway to evaluate the activity of this new compound using dried microdilution panels. The impact of aged broth on dried panels is unknown and is the reason this study was commissioned. However, the testing of tigecycline in dried panels using fresh broth is somewhat problematic. This study was design to measure the impact of aged broth with and without the addition of a BORA when dried tigecycline in broth containing BORA or no BORA panels are used to test tigecycline.

All organisms were tested concurrently using aged broth with or without the addition of a BORA. A subset of selected organism groups were also tested against tigecycline in fresh broth without the addition of a BORA and compared to aged broth.

MATERIALS & METHODS

- Over 3,400 clinical isolates were tested using microdilution panels by Dade Microscan (Dade Behring Inc., Sacramento, CA. USA) according to NCCLS guidelines [3] and manufacturers instructions.
- Each individual isolate was inoculated into the appropriate broth medium.
- Each individual isolate was also inoculated in the appropriate broth medium with the addition of 2% Oxyrase® (a biocatalytic oxygenreducing agent).
- The individual broth with the 2% Oxyrase was incubated at 35°C for 1/2 hour before the organism was inoculated into the broth.
- Each pair of broths (with Oxyrase and without Oxyrase) was inoculated with a single 0.5 McFarland standard of organism.
- Quality Control was performed using the following ATCC strains: E. coli ATCC 25922, P. aeruginosa ATCC 27853, E. faecalis ATCC 29212, and S. aureus ATCC 29213, S.pneumoniae ATCC 49619, and H.influenzae ATCC 49247 [3].

ACKNOWLEDGEMENTS

This study was supported by a grant from Wyeth Pharmaceuticals.

REFERENCES

Sum, P.E. and P. Petersen, Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett, 1999. 9(10): p. 1459-62.

Abbanat, D., M. Macielag, and K. Bush, Novel antibacterial agents for the reatment of serious Gram-positive infections. Expert Opin Investig Drugs, 2003. 12(3): p. 379-99

National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement. NCCLS document M100-S14. Wayne, PA, 2004.

RESULTS

Table 1 provides an overview of the organisms evaluated

 Table 1: Organisms collected October 1, 2001 from 15 countries and evaluated against

Organisms	Number	Organisms	Number	Organisms	Number
Streptococcus agalactiae	100	Staphylococcus epidermidis		Klebsiella pneumoniae	
Streptococcus pyogenes	107	MSSE	89	ESBL	150
Streptococcus pneumoniae		MRSE	150	Non-ESBL	150
PenS	100	Corynebacterium jeikeium	43	Escherichia coli	
PenI	100	Enterococcus faecium	150	ESBL	150
PenR	100	Enterococcus faecalis	150	Non-ESBL	160
MacS	60	Acinetobacter baumanii	120	Citrobacter freundii	140
MacR	60	Acinetobacter lwoffii	60	Citrobacter diversus	15
Staphylococcus aureus		Enterobacter cloacae	151	Moraxella catarrhalis	175
MSSA	150	Enterobacter aerogenes	150	Haemophilus influenzae	
MRSA	140	Klebsiella oxytoca		Beta lactamase +	100
Serratia marcescens	150	ESBL	120	Beta lactamase -	100
		Non-ESBL	120	Citrobacter koserii	

Preliminary Evaluation Results:

Previous to the initiation of this study, an evaluation of the impact of BORA on fresh and ged media was conducted using freshly prepared panels. It was concluded from this study hat the addition of a BORA to aged broth provided similar results to those seen when fresh roth was used. These results are shown in Graph 1.

Graph 1. Evaluation of oxyrase against ATCC strains prior to performing study on 3700



IHMA, Inc. 2122 Palmer Dr. Schaumburg, IL 60173 Tel: (847) 303-5003 Fax: (847) 303-5601 www.ihmainc.com

l in this study.	

Table 2 reflects the range, MIC⁹⁰ and mean dilution difference for tigecycline when organisms are tested in aged broth with or without BORA.

	Range (mcg/mL)		MIC ₉₀ (m	cg/mL)	Mean Dilution Difference		
Organisms	W/O BORA	W/BORA	W/O BORA	W/BORA	(log ₂)		
cinetobacter baumannii (n=120)	0.06-4	0.03-2	2	1	0.778		
cinetobacter lwoffii (n=60)	0.03-2	0.03-1	0.5	0.25	0.867		
itrobacter diversus (n-15)	0.06-1	0.06-1	0.5	0.25	0.667		
itrobacter freundii (n=140)	0.12-2	0.12-2	1	0.5	0.774		
itrobacter koseri (n=35)	0.12-1	0.12-0.25	0.5	0.25	0.758		
orynebacterium, non-spec (n=43)	0.03-0.25	0.03-0.25	0.25	0.12	0.767		
nterobacter aerogenes (n=150)	0.25-4	0.12-4	1	1	0.758		
nterobacter cloacae (n=151)	0.12-8	0.06-8	2	2	0.331		
nterococcus faecalis (n=150)	0.03-0.5	0.06-0.25	0.25	0.12	0.77		
nterococcus faecium (n=150)	0.06-0.25	0.03-0.25	0.25	0.12	0.443		
scherichia coli - ESBL (n=150)	0.12-2	0.06-2	0.5	0.5	0.691		
scherichia coli – nonESBL (n=160)	0.12-2	0.06-1	0.5	0.25	0.756		
aemophilus influenzae (n=200)	0.25-4	0.03-0.5	2	0.12	3.311		
lebsiella oxytoca (n=240)	0.12-2	0.06-2	0.5	0.5	0.355		
lebsiella pneumoniae -ESBL (n=150)	0.25-4	0.25-4	2	2	0.517		
lebsiella pneumoniae -nonESBL (n=150)	0.25-4	0.25-4	1	0.5	0.541		
oraxella catarrhalis (n=175)	≤0.008-0.25	<0.008-0.12	0.12	0.06	1.226		
erratia marcescens (n=150)	0.25-4	0.12-4	1	1	0.793		
taphylococcus aureus, MRSA (n=140)	0.12-1	0.06-0.25	0.5	0.25	0.627		
taphylococcus aureus, MSSA (n=150)	0.12-0.25	0.06-0.5	0.25	0.12	0.708		
aphylococcus epidermidis (n=239)	0.12-2	0.03-1	0.5	0.5	0.766		
treptococcus agalactiae (n=100)	0.06-0.5	0.06-0.12	0.25	0.12	1.031		
treptococcus pneumoniae (n=300)	0.015-0.25	<0.008-0.12	0.12	0.06	0.946		

Quality control results for tigecycline varied based on the organisms tested and the use of a BORA in aged broth. Table 3 gives all quality control results from this study:

Table 3: Quality control results for tigecycline when tested in fresh broth, aged broth without a BORA and aged broth with a BORA.

(mcg/mL)	<0.008	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2
S. aureus A	ATCC 29	213 (0.03-	0.25 mcg/n	nL)						
Fresh Broth						6				
Aged w/o BORA						7	14			
Aged with BORA					1	18	2			
E. coli ATO	CC 2592.	2 (0.03-0.2	5 mcg/mL))						
Fresh Broth						6				
Aged w/o BORA						14	6			
Aged with BORA					5	15				
E. faecalis	ATCC 2	9212 (0.03	-0.12 mcg/	mL)	·				·	·
Fresh Broth					2	4				
Aged w/o BORA					1	18	2			
Aged with BORA				1	17		3			
S. pneumon	niae ATC	C 49619 (0.008-0.03	mcg/mL)						
Fresh Broth				6						
Aged w/o BORA					6	8	2	3		
Aged with BORA				18	1					
H. influenzo	ae ATCO	2 49247 (0.	.06-0.25 m	cg/mL)	·				·	
Fresh Broth					3	3				
Aged w/o BORA							1	5	5	3
Aged with BORA				1	7	6				

A subset of organisms from the E. coli group, K. pneumoniae group, M. catarrhalis group, S. epidermidis group and S. pneumo. groups were further compared. The mode MIC for each group was determined on aged broth with out BORA, aged broth with BORA and fresh broth containing no BORA. The following graphs provide view of the impact BORA in aged broth when testing





Tigecycline is a new promising agent to treat both Gram-positive and negative bacteria. It is important to the microbiologist and physician to have an accurate in vitro evaluation of the activity of tigecycline against known and suspected pathogens. Many laboratories will evaluate tigecycline using dried panels with broth purchased from various suppliers.

This study concludes that dried panels using aged broth can be used when a biocatalytic oxygen-reducing agent (BORA) is added to the broth. The addition of a BORA is especially important when testing organisms like S. pneumoniae and H. influenzae. The testing of tigecycline against fastidious organisms appears to be impacted more by aged broth than some other organisms.

The results seen in this study demonstrate a good correlation between tigecycline testing when fresh broth or aged broth containing a BORA is used. It is unlikely laboratories will obtain accurate quality control results for some organisms without the addition of a BORA if aged broth is used.

It appears that the use of a BORA in aged broth is a viable alternative to using fresh broth each time the testing of tigecycline is performed using broth nicrodilution panels.